Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study
In conclusion GABA-Mo, particularly in the curative protocol, was able to reduce visceral pain and intestinal inflammation, likely through a reinforcement of intestinal barrier integrity, thus representing a suitable approach for the management of abdominal pain, especially in the remission stages of colitis.
Authors
- Giulia Valdiserra (ORCID: https://orcid.org/0000-0003-1616-8644)
- Massimo Bellini (ORCID: https://orcid.org/0000-0002-6387-6443)
- Christian Lambiase (ORCID: https://orcid.org/0000-0002-9565-5039)
- Clara Ciampi (ORCID: https://orcid.org/0000-0002-6455-2723)
- Vanessa D’Antongiovanni (ORCID: https://orcid.org/0000-0002-3303-0674)
- Matteo Fornai (ORCID: https://orcid.org/0000-0002-0812-3959)
- Lorenzo Di Cesare Mannelli (ORCID: https://orcid.org/0000-0001-8374-4432)
- Luca Antonioli (ORCID: https://orcid.org/0000-0003-1241-617X)
- Carolina Pellegrini (ORCID: https://orcid.org/0000-0003-2644-5430)
- Antonio Andrea Grosso (ORCID: https://orcid.org/0000-0001-5973-789X)
- Laura Benvenuti (ORCID: https://orcid.org/0000-0001-6576-5053)
- Elena Lucarini (ORCID: https://orcid.org/0000-0002-3459-2660)
- Lorenzo Cancelli
- Clelia Di Salvo
- Carla Ghelardini
Institutions
- University of Pisa (IT)
- University of Florence (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3389/fphar.2024.1466824
- Citations
- 2
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.93